Verzoni E - Search Results

1

Platania M, Verzoni E, Vitali M. Platania M, et al. Among authors: verzoni e. Tumori. 2015 Mar-Apr;101(2):246-8. doi: 10.5301/tj.5000257. Epub 2015 Apr 16. Tumori. 2015. PMID: 25908038

2

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.

3

Neuroendocrine tumors of the larynx: a clinical report and literature review.

Procopio G, Ricotta R, Fusi A, Celio L, De Dosso S, Catena L, Ferrari L, Quattrone P, Verzoni E, Bajetta E. Procopio G, et al. Among authors: verzoni e. Tumori. 2006 Jan-Feb;92(1):72-5. Tumori. 2006. PMID: 16683387

4

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R. Bajetta E, et al. Among authors: verzoni e. Cancer Chemother Pharmacol. 2007 Apr;59(5):637-42. doi: 10.1007/s00280-006-0306-6. Epub 2006 Aug 26. Cancer Chemother Pharmacol. 2007. PMID: 16937105

5

Renal cell cancer and sorafenib: skin toxicity and treatment outcome.

Bajetta E, Procopio G, Verzoni E, Catena L, De Dosso S, Platania M, Gevorgyan A. Bajetta E, et al. Among authors: verzoni e. Tumori. 2007 Mar-Apr;93(2):201-3. doi: 10.1177/030089160709300216. Tumori. 2007. PMID: 17557570

6

Pulmonary carcinoid tumours: indolent but not benign.

De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, Verzoni E. De Dosso S, et al. Among authors: verzoni e. Oncology. 2007;73(3-4):162-8. doi: 10.1159/000127382. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418008

7

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.

Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. Procopio G, et al. Among authors: verzoni e. Oncology. 2007;73(3-4):204-9. doi: 10.1159/000127387. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418013

8

Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer.

Bajetta E, Verzoni E, Ferrario E, Dotti K, Gevorgyan A, Celio L. Bajetta E, et al. Among authors: verzoni e. Tumori. 2009 Jan-Feb;95(1):43-7. doi: 10.1177/030089160909500108. Tumori. 2009. PMID: 19366055 Clinical Trial.

9

Management of advanced genitourinary tumors.

Pietrantonio F, Biondani P, Verzoni E, Procopio G. Pietrantonio F, et al. Among authors: verzoni e. Tumori. 2012 Mar-Apr;98(2):264-6. doi: 10.1177/030089161209800214. Tumori. 2012. PMID: 22677995

10

New perspectives in advanced genitourinary malignancies.

Biondani P, Procopio G, Pietrantonio F, de Braud F, Verzoni E. Biondani P, et al. Among authors: verzoni e. Tumori. 2012 Mar-Apr;98(2):267-9. doi: 10.1177/030089161209800215. Tumori. 2012. PMID: 22677996

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

168 results

Search Page

Filters